

血液内科学研究分野 (原研内科)

論文

A 欧文

A-a

- 1 . Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, Komatsu N, Nakashima Y, Yoshida C, Fukuhara N, Usuki K, Yamauchi T, Asada N, Asou N, Choi I, Miyazaki Y, Honda H, Okubo S, Kurokawa M, Zhou Y, Zha J, Potluri J, Matsumura I: Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. *Jpn J Clin Oncol* 52(1): 29-38,2022. doi: 10.1093/jjco/hyab170. (IF: 2.4) *
- 2 . Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, Tanaka M, Kako S, Matsuda M, Yokoyama H, Ishikawa Y, Taniguchi Y, Hagihara M, Ozawa Y, Ueda Y, Hirano D, Sakura T, Tsuji M, Kamae T, Fujita H, Hiramoto N, Onoda M, Fujisawa S, Hatta Y, Dobashi N, Nishiwaki S, Atsuta Y, Kobayashi Y, Hayakawa F, Ohtake S, Naoe T, Miyazaki Y: Dasatinib-based Two-step Induction for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Blood Adv* 6(2): 624-636,2022. doi: 10.1182/bloodadvances.2021004607. (IF: 7.5) *
- 3 . Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Utsunomiya A, Ueda R, Ishida T: Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab. *Br J Haematol* 196(3): 629-638,2022. doi: 10.1111/bjh.17895. (IF: 6.5) *
- 4 . Kogure Y, Kameda T, Koya J, Yoshimitsu M, Nosaka K, Yasunaga JI, Imaizumi Y, Watanabe M, Saito Y, Ito Y, McClure MB, Tabata M, Shingaki S, Yoshifuji K, Chiba K, Okada A, Kakiuchi N, Nannya Y, Kamiunten A, Tahira Y, Akizuki K, Sekine M, Shide K, Hidaka T, Kubuki Y, Kitanaka A, Hidaka M, Nakano N, Utsunomiya A, Sica RA, Acuna-Villaorduna A, Janakiram M, Shah UA, Ramos JC, Shibata T, Takeuchi K, Takaori-Kondo A, Miyazaki Y, Matsuoka M, Ishitsuka K, Shiraishi Y, Miyano S, Ogawa S, Ye BH, Shimoda K, Kataoka K: Whole-genome landscape of adult T-cell leukemia/lymphoma. *Blood* 139(7): 967-982,2022. doi: 10.1182/blood.2021013568. (IF: 20.3) *
- 5 . Ikebe E, Shimosaki S, Hasegawa H, Iha H, Tsukamoto Y, Wang Y, Sasaki D, Imaizumi Y, Miyazaki Y, Yanagihara K, Hamaguchi I, Morishita K: TAS-116 (pimitespib), a heat shock protein 90 inhibitor, shows efficacy in preclinical models of adult T-cell leukemia. *Cancer Sci* 113(2): 684-696,2022. doi: 10.1111/cas.15204. (IF: 5.7) *
- 6 . Kako S, Hayakawa F, Miyamura K, Tanaka J, Imai K, Kanda J, Morishima S, Uchida N, Doki N, Ikegame K, Ozawa Y, Takada S, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Ichinohe T, Fukuda T, Atsuta Y, Kanda Y: Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission. *Transplant Cell Ther* 28(3): 161.e1-161.e10,2022. doi: 10.1016/j.jtct.2021.11.021. (IF: 3.2) *
- 7 . Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuo Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F: Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. *Blood* 139(12): 1850-1862,2022. doi: 10.1182/blood.2021011921. (IF: 20.3) *
- 8 . Iyama K, Ikeda S, Koga S, Yoshimuta T, Kawano H, Tsuji S, Ando K, Matsushima K, Tada H, Kawashiri MA, Kawakami A, Maemura K: Acute Coronary Syndrome Developed in a 17-year-old Boy with Sitosterolemia Comorbid with Takayasu Arteritis: A Rare Case Report and Review of the Literature. *Intern Med* 61(8): 1169-1177,2022. doi: 10.2169/internalmedicine.8288-21. (IF: 1.2) *
- 9 . Kato T, Imaizumi Y, Miyazaki Y: Nationwide Hospital-Based Survey of Adult T-Cell Leukemia/Lymphoma in Japan. *Viruses* 14(4): 791,2022. doi: 10.3390/v14040791. (IF: 4.7) *
- 10 . Ueda Y, Usuki K, Fujita J, Matsumura I, Aotsuka N, Sekiguchi N, Nakazato T, Iwasaki H, Takahara-Matsubara M, Sugimoto S, Goto M, Naoe T, Kizaki M, Miyazaki Y, Aakashi K: Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes. *Cancer Sci* 113(4): 1377-1392,2022. doi: 10.1111/cas.15245. (IF: 5.7) *
- 11 . Dai YT, Zhang F, Fang H, Li JF, Lu G, Jiang L, Chen B, Mao DD, Liu YF, Wang J, Peng LJ, Feng C, Chen HF, Mu JX, Zhang QL, Wang H, Ariffin H, Moy TA, Wang JH, Lou YJ, Chen SN, Wang Q, Liu H, Shan Z, Matsumura I, Miyazaki Y, Yasuda T, Dou LP, Yan XJ, Yan JS, Yeoh AE, Wu DP, Kiyoi H, Hayakawa F, Jin J, Wang SY, Sun XJ, Mi JQ, Chen Z, Huang JY, Chen SJ: Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases. *Proc Natl Acad Sci US A* 119(15): e2120787119,2022. doi: 10.1073/pnas.2120787119. (IF: 11.1) *

- 12 . Iida H, Imada K, Ueda Y, Kubo K, Yokota A, Ito Y, Kiguchi T, Hata T, Nawa Y, Ikezoe T, Uchida T, Morita Y, Kawashima I, Chiba M, Morimoto K, Hirooka S, Miyazaki Y, Ohno R, Naoe T; Study Group : A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia. *Int J Hematol* 115(5): 694-703,2022. doi: 10.1007/s12185-022-03307-x. (IF: 2.1) *
- 13 . Platzbecker U, Chromik J, Krönke J, Handa H, Strickland S, Miyazaki Y, Wermke M, Sakamoto W, Tachibana Y, Taube T, Germing U: Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies. *BMC Cancer* 22(1): 569,2022. doi: 10.1186/s12885-022-09622-0. (IF: 3.8) *
- 14 . Chen C, Man N, Liu F, Martin GM, Itonaga H, Sun J, Nimer SD: Epigenetic and Transcriptional Regulation of Innate Immunity in Cancer. *Cancer Res* 82(11): 2047-2056,2022. doi: 10.1158/0008-5472.CAN-21-3503. (IF: 11.2) *
- 15 . Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kimura T, Kanda J, Fukuda T, Atsuta Y, Ishiyama K: Myeloablative versus reduced-intensity conditioning with fludarabine/busulfan for myelodysplastic syndrome: A propensity score-matched analysis. *Transplant Cell Ther* 28(6): 323.e1-323.e9,2022. doi: 10.1016/j.jctc.2022.03.011. (IF: 3.2) *
- 16 . Tsukamoto Y, Umeda M, Muto Y, Sugimoto T, Yamauchi M, Ando K, Ariyoshi K : Severe Anemia Due to Cold Agglutinin Syndrome in a COVID-19 Patient with IgM Monoclonal Gammopathy of Undetermined Significance Successfully Treated with Corticosteroids. *Intern Med* 61(11): 1789-1793,2022. doi: 10.2169/internalmedicine.8647-21. (IF: 1.2) *
- 17 . Wada Y, Sato T, Hasegawa H, Matsudaira T, Nao N, Coler-Reilly ALG, Tasaka T, Yamauchi S, Okagawa T, Momose H, Tanio M, Kuramitsu M, Sasaki D, Matsumoto N, Yagishita N, Yamauchi J, Araya N, Tanabe K, Yamagishi M, Nakashima M, Nakahata S, Iha H, Ogata M, Muramatsu M, Imaizumi Y, Uchimaru K, Miyazaki Y, Konnai S, Yanagihara K, Morishita K, Watanabe T, Yamano Y, Saito M: RAISING is a high-performance method for identifying random transgene integration sites. *Commun Biol* 5(1): 535,2022. doi: 10.1038/s42003-022-03467-w. (IF: 5.9) *
- 18 . Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novak J, Jędrzejczak WW, Thomas X, Ojeda-Urbe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva LT, Demeter J, Griffiths EA, Yee KW, Issa JJ, Bewersdorff JP, Keer HN, Hao Y, Azab M, Döhner H: Prospective Comparison of Outcomes with Azacitidine and Decitabine in AML Patients Ineligible for Intensive Chemotherapy. *Blood* 140(3): 285-289,2022. doi: 10.1182/blood.2022015832. (IF: 20.3) *
- 19 . Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group: Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. *Int J Hematol* 116(2): 228-238,2022. doi: 10.1007/s12185-022-03347-3. (IF: 2.1) *
- 20 . Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, Choi I, Imaizumi Y, Kato K, Kurosawa M, Kusumoto S, Miyagi T, Ohtsuka E, Sasaki O, Shibayama H, Shimoda K, Takamatsu Y, Takano K, Yonekura K, Makita S, Taguchi J, Gillings M, Onogi H, Tobinai K: Oral HDAC Inhibitor Tucidinostat (HBI-8000) in Patients with Relapsed or Refractory Adult T-cell Leukemia/Lymphoma: Phase IIb Results. *Cancer Sci* 113(8): 2778-2787,2022. doi: 10.1111/cas.15431. (IF: 5.7) *
- 21 . Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B: Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. *Blood* 140(12): 1345-1377,2022. doi: 10.1182/blood.2022016867. (IF: 20.3) *
- 22 . Takeda J, Yoshida K, Nakagawa MM, Nannya Y, Yoda A, Saiki R, Ochi Y, Zhao L, Okuda R, Qi X, Mori T, Kon A, Chiba K, Tanaka H, Shiraishi Y, Kuo MC, Kerr CM, Nagata Y, Morishita D, Hiramoto N, Hangaishi A, Nakazawa H, Ishiyama K, Miyano S, Chiba S, Miyazaki Y, Kitano T, Usuki K, Sezaki N, Tsurumi H, Miyawaki S, Maciejewski JP, Ishikawa T, Ohyashiki K, Ganser A, Heuser M, Thol F, Shih LY, Takaori-Kondo A, Makishima H, Ogawa S: Amplified EPOR/JAK2 genes define a unique subtype of acute erythroid leukemia. *Blood Cancer Discov* 3(5): 410-427,2022. doi: 10.1158/2643-3230.BCD-21-0192. (IF: 11.2) *
- 23 . Itonaga H, Kida M, Hamamura A, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Kataoka K, Katayama Y, Ota S, Matsuoka KI, Kondo T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Miyazaki Y, Ishiyama K: Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. *Hematol Oncol* 40(4): 752-762,2022. doi: 10.1002/hon.2991. (IF: 3.3) *
- 24 . Tanaka N, Mori S, Kiyotani K, Ota Y, Gotoh O, Kusumoto S, Nakano N, Suehiro Y, Ito A, Choi I, Ohtsuka E, Hidaka M, Nosaka K, Yoshimitsu M, Imaizumi Y, Iida S, Utsunomiya A, Noda T, Nishikawa H, Ueda R, Ishida T: Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. *Haematologica* 107(10): 2418-2431,2022. doi: 10.3324/haematol.2021.280352. (IF: 10.1) *

- 25 . Senju C, Nakazawa Y, Shimada M, Iwata D, Matsuse M, Tanaka K, Miyazaki Y, Moriwaki S, Mitsutake N, Ogi T: Aicardi-Goutières syndrome with SAMHD1 deficiency can be diagnosed by unscheduled DNA synthesis test. *Front Pediatr* 10: 1048002,2022. doi: 10.3389/fped.2022.1048002. (IF: 2.6) *
- 26 . Fujioka M, Itonaga H, Furumoto T, Sakaki C, Sakamoto H, Kato T, Horai M, Taguchi M, Sawayama Y, Taguchi J, Imaizumi Y, Yoshida S, Moriuchi Y, Miyazaki Y (12月): Clinical features of non-infectious pulmonary complications after donor lymphocyte infusion in post-transplant patients: The Nagasaki Transplant Group Experience. *Transpl Immunol* 75: 101707,2022. doi: 10.1016/j.trim.2022.101707. (IF: 1.5) ○*
- 27 . Sakamoto H, Ando K, Imaizumi Y, Mishima H, Kinoshita A, Kobayashi Y, Kitanosono H, Kato T, Sawayama Y, Sato S, Hata T, Nakashima M, Yoshiura KI, Miyazaki Y: Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth. *Cancer Sci* 113(12): 4092-4103,2022. doi: 10.1111/cas.15550. (IF: 5.7) ○★◇*
- 28 . Ikezoe T, Ando K, Onozawa M, Yamane T, Hosono N, Morita Y, Kiguchi T, Iwasaki H, Miyamoto T, Matsubara K, Sugimoto S, Miyazaki Y, Kizaki M, Akashi K: Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan. *Cancer Sci* 113(12): 4258-4266,2022. doi: 10.1111/cas.15458. (IF: 5.7) *
- 29 . Otsubo R, Yano H, Itonaga H, Iwasaki K, Segawa K, Nagayasu T: Severe thrombocytopenia and anemia as an initial presentation of breast cancer: A case report. *Clin Case Rep* 10(12): e6762,2022. doi: 10.1002/ccr3.6762. (IF: 0.7) *

A-e-1

- 1 . Shimizu T, Yonemori K, Koyama T, Katsuya Y, Sato J, Fukuhara N, Yokoyama H, Iida H, Ando K, Fukuhara S, Miyake H, Tanoue Y, Tozaki H, Mizutani A, Morishita D, Takeyama K, Yamamoto N: A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors. *J Clin Oncol* 40(Suppl 1): 3080,2022. doi: https://doi.org/10.1200/JCO.2022.40.16_suppl.3080.
- 2 . Hatta Y, Sato A, Kada A, Moriya Saito A, Hayakawa F, Watanabe A, Sakamoto T, Miura K, Shimizu Y, Kanda J, Onishi Y, Asada N, Okamoto Y, Imai C, Oshima K, Koh K, Manabe A, Horibe K, Kiyoi H, Matsumura I, Miyazaki Y: Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study. *Blood* 140(Suppl 1): 124-126,2022. doi: <https://doi.org/10.1182/blood-2022-156613>.
- 3 . Makishima H, Saiki R, Nannya Y, Korotev SC, Gurnari C, Takeda J, Momozawa Y, Best S, Krishnamurthy P, Yoshizato T, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraiishi Y, Nagata Y, Kakiuchi N, Onizuka M, Chiba K, Tanaka H, Kon A, Ochi Y, Nakagawa MM, Okuda R, Mori T, Yoda A, Itonaga H, Miyazaki Y, Sanada M, Ishikawa T, Chiba S, Tsurumi H, Kasahara S, Müller-Tidow C, Takaori-Kondo A, Ohyashiki K, Kiguchi T, Matsuda F, Jansen JH, Polprasert C, Blombery P, Kamatani Y, Miyano S, Malcovati L, Haferlach T, Kubo M, Cazzola M, Kulasekararaj A, Godley LA, Maciejewski JP, Ogawa S: Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies. *Blood* 140(Suppl 1): 208-210,2022. doi: <https://doi.org/10.1182/blood-2022-158851>.
- 4 . Santini V, Platzbecker U, Fenaux P, Giagounidis A, Miyazaki Y, Sekeres M A, Xiao Z, Sanz G, Hoef M V, Ma F, Hertle S, Ramos P M, Zeidan A M: Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2). *Blood* 140(Suppl 1): 1340-1342,2022. doi: <https://doi.org/10.1182/blood-2022-160282>.
- 5 . Zeidan AM, Ando K, Rauzy O, Turgut M, Wang M, Cairoli R, Hou H, Kwong Y, Sangerman MA, Meers S, Pullarkat VA, Santini V, Malek K, Kiertsman F, Lyu J, Ramos PM, Fenaux P, Miyazaki Y, Platzbecker U: Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS). *Blood* 140(Suppl 1): 2063-2065,2022. doi: <https://doi.org/10.1182/blood-2022-158612>.
- 6 . Chen C, Man N, Tamiro F, Hossack K, Poveda J, Bilbao D, Mas G, Duffort S, Martinez C, Itonaga H, Liu F, Chapman-Fredricks J R, Nimer S D: The NLRC4 Inflammasome Drives Myelodysplastic Syndrome By Linking Epigenetic Reprogramming and Innate Immune Signaling. *Blood* 140(Suppl 1): 3009-3010,2022. doi: <https://doi.org/10.1182/blood-2022-160075>.
- 7 . Itonaga H, Mookhtiar A K, Greenblatt S, Liu F, Martinez C, Grozovsky R, Bilbao D, Rains M, Hamard P, Sun J, Umeano A, Duffort S, Chen C, Man N, Martin G M, Schürer S, Nimer S D: Tyrosine Phosphorylation of CARM1 Promotes Its Enzymatic Activity and Alters Its Target Specificity in Myeloid Neoplasms with Hyperactivated JAK2 . *Blood* 140(Suppl 1): 3021-3022,2022. doi: <https://doi.org/10.1182/blood-2022-156887>.
- 8 . Daver N, Ikezoe T, Watts J, Hosono N, Ogawa Y, Miyazaki Y, Erba H.P, Affinito J, Brooks E, Eguchi K, Cai H, Xu B, Stoudemire J, Hitron M, Watanabe A, Komarnitsky P, Yuda J: Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m). *Blood* 140(Suppl 1): 3371-3372,2022. doi: <https://doi.org/10.1182/blood-2022-167674>.

- 9 . Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Taniguchi Y, Tanaka M, Kako S, Ichinohe T, Fukuda T, Atsuta Y, Ohtake S, Ishikawa Y, Kiyoi H, Matsumura I, Miyazaki Y: Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL: JALSG Ph+ALL TKI- SCT Study. *Blood* 140(Suppl 1): 6030-6032,2022. doi: <https://doi.org/10.1182/blood-2022-165864>.
- 10 . Yokoyama Y, Ando K, Fukuhara N, Iida H, Fukuhara S, Miyake H, Tanoue Y, Yamamoto M, Tozaki H, Mizutani A, Morishita D, Takeyama K, Shimizu T, Yamamoto N: A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort. *Blood* 140(Suppl 1): 6211-6212,2022. doi: <https://doi.org/10.1182/blood-2022-157241>.
- 11 . Okuda R, Ochi Y, Chonabayashi K, Hiramoto N, Sanada M, Handa H, Kasahara S, Sato S, Kanemura N, Kitano T, Mizuki Watanabe M, Kern W, Creignou M, Shiraishi Y, Watanabe M, Usuki K, Imashuku S, Hellström-Lindberg E, Haferlach T, Chiba S, Sezaki N, Shih LY, Miyazaki Y, Yoshida Y, Ishikawa T, Ohyashiki K, Atsuta Y, Shiozawa Y, Miyano S, Makishima H, Nannya Y, Ogawa S: Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10). *Blood* 140(Suppl 1): 6902-6904,2022. doi: <https://doi.org/10.1182/blood-2022-168213>.
- 12 . Pfeilstocker M, Tuechler H, Ades L, Cermak J, Chermat F, Della Porta MG, Fenaux P, Garcia-Manero G, Germing U, Haase D, Kuendgen A, Luebbert M, Magalhaes S M M, Malcovati L, Miyazaki Y, Sanz G, Santini V, Sekeres MA, Walter MJ, Valent P, Greenberg PL: Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories. *Blood* 140(Suppl 1): 6976-6978,2022. doi: <https://doi.org/10.1182/blood-2022-158671>.

B 邦文

B-a

- 1 . 澤山 靖, 加藤丈晴, 渡辺春香, 山田悠一, 藤岡真知子, 佐藤信也, 馬場真紀, 安東恒史, 宮崎禎一郎, 神尾芳幸, 中道一生, 雪竹基弘, 今泉芳孝, 宮崎泰司: 菌状息肉症に合併した進行性多巣性白質脳症. *臨床血液* 63(3): 206-210, 2022.
- 2 . 渡辺華子, 小池雄太, 早稲田 朋香, 福地麗雅, 岩永 聡, 山田悠一, 安東恒史, 今泉芳孝, 室田浩之: 多発皮膚腫瘍で発症し、成人T細胞白血病リンパ腫との鑑別を要した原発性皮膚未分化大細胞リンパ腫の1例. *西日本皮膚科* 84(2): 140-144, 2022.
- 3 . 古本嵩文, 牧山純也, 鳥山 愛生, 新野大介, 波多智子, 森内幸美, 宮崎泰司: 移植後cyclophosphamideを用いたHLA半合致移植を施行した骨髄性肉腫合併骨髄異形成症候群. *臨床血液* 63(5): 341-346, 2022.
- 4 . 新山侑生, 澤山 靖, 藤岡真知子, 加藤丈晴, 糸永英弘, 佐藤信也, 安東恒史, 今泉芳孝, 新野大介, 木下克美, 渡辺嘉久, 長井一浩, 宮崎泰司: 骨髄濃縮により同種骨髄移植を施行し得た抗IgA抗体を有するIgA非欠損例. *日本輸血細胞治療学会誌* 68(4): 491-495, 2022.
- 5 . 安東恒史, 塚本 裕, 梅田雅孝, 武藤祐子, 杉本尊史, 山内桃子, 有吉紅也, 宮崎泰司: COVID-19を契機に診断され、ステロイドにて軽快するも新型コロナウイルスワクチン接種によって増悪した寒冷凝集素症候群. *長崎医学会雑誌* 97(3): 254-258, 2022.

B-b

- 1 . 宮崎泰司: 白血病の進歩 . *日本内科学会雑誌* 113(3): 572-577, 2022.
- 2 . 宮崎泰司: VII.白血病と類縁疾患-骨髄異形成症候群. *血液疾患のすべて*. 日本医師会雑誌 151(特別1): S226-S228, 2022.
- 3 . 安東恒史, 宮崎泰司: 放射線被ばくと造血障害. *臨床血液* 63(9): 981-990, 2022.
- 4 . 加藤丈晴, 今泉芳孝: 血液専門医のための模擬テスト32. *血液内科* 85(4): 640, 2022.
- 5 . 安東恒史, 宮崎泰司: MDSにおける炎症-VEXAS症候群とMDS- . 別冊BIO Clinica 11(2): 66-68, 2022.
- 6 . 加藤丈晴, 今泉芳孝: 血液専門医のための模擬テスト32.-解答と解説-. *血液内科* 85(5): 773-774, 2022.

B-c

- 1 . 今泉芳孝, 宮崎泰司: 2. HTLV-1感染症. *感染症最新の治療2022-2024*: 225-226, 2022.
- 2 . 宮崎泰司: 17-6 造血器腫瘍のWHO分類. *内科学* 第12版: 38-42, 2022.
- 3 . 宮崎泰司, 藪藤由美子, 栗原 治: 第6章 線量評価 6-2 生体試料による線量評価. *被ばく医療線量手引き*: 61-65, 2022.
- 4 . 渡辺春香, 宮崎泰司: IV 白血球系疾患 1. 骨髄系 1) 骨髄系腫瘍のWHO分類. *専門医のための血液病学*: 116-121, 2022.
- 5 . 安東恒史, 宮崎泰司: II. 血球系疾患 6. MDSに対する予後予測. *EBM血液疾患の治療*: 42-46, 2022.

B-d

1. 宮崎泰司：令和4年度 原爆犠牲者慰霊祭に際して- 講和. 朋百 157(秋号): 9-11, 2022.
2. 宮崎泰司：拠点副本部長あいさつ. 放射線災害・医科学拠点 ニュースレター 11: 2, 2022.

B-e-1

1. 森 沙耶香, 長谷川寛雄, 鶴田一人, 宮崎泰司, 柳原克紀：2. 急性骨髄性白血病(APL)症例における全トランス型レチノイン酸(ATRA)治療に伴う好中球系細胞の形態学的変化. 日本臨床検査血液学会雑誌 23(1): 136-147, 2022.
2. 中崎久美, 竹崎俊晶, 正本庸介, 宮崎泰司, 三谷絹子, 黒川峰夫：低リスク骨髄異形成症候群の治療選択と予後：全国多施設共同研究. 日本内科学会雑誌 111(臨時増刊): 183, 2022.
3. 新山侑生, 澤山 靖, 藤岡真知子, 加藤丈晴, 佐藤信也, 安東恒史, 今泉芳孝, 木下克美, 長井一浩, 宮崎泰司：抗IgA抗体を有するIgA非欠損例における非溶血性輸血副作用. 日本輸血細胞治療学会誌 68(1): 79, 2022.
4. 林 洋子, 澤本怜奈, 濱辺真奈, 長田翔斗, 田崎真佑子, 松崎佳歩, 加藤丈晴, 下川 功：血球貪食症候群を合併しびまん性肺胞出血を来し死亡した亜急性壊死性リンパ節炎の一剖検例. 日本病理学会会誌 111(1): 299, 2022.
5. 下農真弘, 浅井 幸, 里見直義, 加藤丈晴, 室田浩之：巨大原発性皮膚びまん性大細胞型B細胞リンパ腫, 下肢型の1例. 西日本皮膚科 84(2): 157, 2022.
6. 桐野祐子, 小林裕児, 榎 智佳, 蓬莱真喜子, 吉田真一郎, 三浦史郎：ステロイド長期内服中にEBV-positive mucocutaneous ulcerを発症した1例. 臨床血液 63(6): 694, 2022.
7. 新山侑生, 糸永英弘, 松岡優毅, 高崎由美, 宮崎泰司：ダサチニブが奏効したJAK2-V617F変異を有するBCR-ABL1陽性慢性骨髄性白血病. 臨床血液 63(6): 703, 2022.
8. 西村紗央里, 加藤丈晴, 糸永英弘, 佐藤信也, 安東恒史, 澤山 靖, 三好寛明, 今泉芳孝, 大島孝一, 宮崎泰司：口腔内に生じたHIV陰性・EBV陰性の形質芽球性リンパ腫. 臨床血液 63(6): 709, 2022.
9. 古本嵩文, 加藤丈晴, 今泉芳孝, 新山侑生, 糸永英弘, 佐藤信也, 安東恒史, 澤山 靖, 岡野慎士, 大島孝一, 宮崎泰司：染色体異常t(8;22)(q24.1;q11.2)を有する再発原発性体腔液リンパ腫類似リンパ腫. 日本リンパ網内系学会会誌 62: 94, 2022.
10. 林田章也, 長谷川寛雄, 森 沙耶香, 鶴田一人, 淵上麻衣, 山内俊輔, 加藤丈晴, 宮崎泰司, 柳原克紀：フローサイトメトリー検査が鑑別に有用であった芽球型形質細胞様樹状細胞腫瘍の一例. 日本検査血液学会雑誌 23(学術集会): S184, 2022.
11. 牧島秀樹, 佐伯龍之介, 南谷泰仁, 竹田淳恵, 桃沢幸秀, 熱田由子, 中川正宏, 宮崎泰司, 鶴見 寿, 笠原千嗣, 高折晃史, 大屋一馬, 木口 亨, 松田文彦, 宮野 悟, 小川誠司：全ゲノム/全エクソーム解析による生殖細胞系列多型の探索 DDX41胚細胞変異陽性骨髄腫瘍のリスク定量と臨床的特徴. 日本癌学会総会記事 81回: S8-4, 2022.
12. 中森瑞季, 頭金正博, 片山早紀, 柴田侑裕, 楠本 茂, 野坂生郷, 今泉芳孝, 末廣陽子, 宇都宮 與, 上田龍三, 石田高司, 石塚賢治：モガムリズマブ投与患者における重篤な皮膚障害の発症に関連するバイオマーカーの探索研究. 日本臨床薬理学会学術総会抄録集 43回: 1-C-O02-3, 2022.

論文研究業績集計表

論文数一覧

	A-a	A-b	A-c	A-d	A-e	合計	SCI	B-a	B-b	B-c	B-d	B-e	合計	総計
2022	29	0	0	0	12	41	29	5	6	5	2	12	30	71

学会発表数一覧

	A-a	A-b シンポ・シナム	A-b 学会	合計	B-a	B-b シンポ・シナム	B-b 学会	合計	総計
2022	1	0	13	14	1	1	39	41	55

論文総数に係る教員生産係数一覧

	欧文論文総数 論文総数	教員生産係数 (欧文論文)	SCI 掲載論文数 欧文論文総数	教員生産係数 (SCI 掲載論文)
2022	0.577	5.125	0.707	3.625

Impact Factor 値一覧

	Impact Factor	教員当たりのImpact Factor	論文当たりのImpact Factor
2022	205.200	25.650	7.076